CCHT(SZ:000661) HTSC·2025-09-03 06:23Investment Rating - The investment rating for the company is "Buy" with a target price of 144.48 RMB [7][5]. Core Views - The company's revenue for 1H25 was 6.603 billion RMB, with a net profit attributable to the parent company of 0.983 billion RMB, reflecting a year-on-year decline of 0.5% and 42.85% respectively. The revenue stability is attributed to steady sales of growth hormone and stable performance in the real estate sector, while the profit decline is mainly due to increased sales, management, and R&D expenses during the innovation transition [1][5]. - The company is expected to stabilize its revenue in 2025, driven by an increase in long-acting growth hormone revenue and the expansion of non-growth hormone product sales. The approval and rapid market entry of IL-1β is also anticipated to contribute positively [1][5]. - The long-term growth trajectory is supported by the commercialization of pipelines in various therapeutic areas, including oncology, autoimmune diseases, pediatrics, and gynecology [1][5]. Summary by Sections Financial Performance - In 1H25, the company reported revenue of 6.603 billion RMB and a net profit of 0.983 billion RMB, with a year-on-year decline of 0.5% and 42.85% respectively. The decline in profit is primarily due to increased expenses related to the company's innovation transition [1][5]. - The company expects revenue to stabilize in 2025, with a projected net profit decline due to ongoing investments in sales and management during the transition period [1][5]. Product Development - The company has established multiple technology platforms for drug development, including ADC, small nucleic acids, long-acting release, and dual antibodies/multifunctional macromolecules. Currently, 8 molecules across 11 indications are in clinical III phase and NDA stages [3]. - Key therapeutic areas for future growth include endocrine disorders, immunology, and oncology, with several promising candidates in the pipeline [3]. Market Outlook - The company anticipates steady revenue growth in 2025, driven by the expansion of growth hormone sales and the introduction of new products in gynecology, pediatrics, and oncology [2][5]. - The approval of the IL-1β drug is expected to generate significant sales in its first year, with further growth anticipated as additional indications are pursued [2][5].